Unity Biotechnology(UBX.US)

Company Encyclopedia
View More
name
Unity Biotechnology
UBX.US
Unity Biotechnology, Inc., a biotechnology company, engages in the research and development of therapeutics to slow, halt, or reverse diseases of aging. Its lead drug candidate includes UBX1325, which is Phase 2 clinical trial for the treatment of age-related diseases of the eye, including diabetic macular edema, age-related macular degeneration, and diabetic retinopathy. The company also develops UBX1967 for the treatment of ophthalmologic diseases; UBX2048, a Tie2/VEGF bispecific; UBX2050, a human anti-Tie2 agonist monoclonal antibody for the treatment of eye diseases; and UBX2089, an a-Klotho hormone drug candidate for multiple neurology indications. The company was formerly known as Forge, Inc.
1.906 T
UBX.USMarket value -Rank by Market Cap -/-

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Unity Biotechnology Files Dissolution Certificate Amid Cost-Cutting

    Unity Biotechnology has filed a dissolution certificate as part of its cost-cutting strategy following the ASPIRE study data disclosure. The company terminated its lease for office and lab space effective March 31, 2026. The dissolution was approved by the Board and stockholders, and the stock is no longer transferable. Analysts rate UNBX stock as a Hold with a $2.00 price target, but Spark's AI Analyst considers it an Underperform due to financial challenges and a bearish trend. Unity focuses on therapeutics for age-related diseases.

    Tip Ranks·
    US
    UBX
    0.00%
    Tip Ranks·
    US
    UBX
    0.00%

    UNITY Biotechnology Files for Voluntary Dissolution, Begins Liquidation Process After Shareholder Approval

    UNITY Biotechnology Inc. has initiated its voluntary dissolution process following shareholder approval. The company has entered a Lease Termination Agreement for its South San Francisco office, terminating the lease early on March 31, 2026. A certificate of dissolution was filed with the Delaware Secretary of State on September 26, 2025, effective the same day. As part of this process, UNITY has closed its transfer books, restricting the transfer of its common stock except in limited circumstances.

    Reuters·
    US
    UBX
    0.00%
    Reuters·
    US
    UBX
    0.00%

    UNITY Biotechnology Inc. Conducted Special Stockholder Meeting

    UNITY Biotechnology Inc. held a special stockholder meeting on September 18, 2025, where stockholders approved two key proposals: the liquidation and dissolution of the company, and the adjournment of the meeting, which was deemed unnecessary. The board of directors now has the authority to proceed with the dissolution at their discretion.

    Reuters·
    US
    UBX
    0.00%
    Reuters·
    US
    UBX
    0.00%

    Unity Biotechnology Approves Company Liquidation Plan

    Unity Biotechnology has approved a liquidation plan following a special stockholder meeting on September 18, 2025. Stockholders voted in favor of the Dissolution Proposal, allowing the Board of Directors to proceed with the dissolution. The current analyst rating for UNBX stock is a Hold with a $2.00 price target, but Spark's AI Analyst rates it as Underperform due to financial challenges and a bearish trend. Unity Biotechnology focuses on developing therapeutics for aging-related diseases and has a market cap of $998.3K.

    Tip Ranks·
    US
    UBX
    0.00%
    Tip Ranks·
    US
    UBX
    0.00%

    UNITY Biotechnology Inc. Announces Date for Special Stockholders Meeting

    UNITY Biotechnology Inc. has scheduled a special stockholders meeting for September 18, 2025, to be held virtually. Stockholders will vote on the proposed dissolution of the company. This announcement was published via EDGAR by the U.S. Securities and Exchange Commission.

    Reuters·
    US
    UBX
    0.00%
    Reuters·
    US
    UBX
    0.00%
    © 2025 Longbridge｜Disclaimer